Abstract
Pharmacologic therapy for pediatric inflammatory bowel disease (IBD) can consist of topical therapies as well as those therapies that exert a direct effect on the host immune system. Traditionally, thiopurines have been the first line immunomodulatory agents used to treat pediatric IBD. Increasing awareness of rare but potentially life-threatening malignancies that have been associated with thiopurine use as well as cases of intolerance or lack of response to thiopurine agents has served to promote increasing utilization of another immunomodulator, methotrexate. Given once a week, either parenterally or orally, methotrexate has demonstrated efficacy in pediatric Crohn' disease with less proven efficacy in pediatric ulcerative colitis.
| Original language | English (US) |
|---|---|
| Title of host publication | Pediatric Inflammatory Bowel Disease, Second Edition |
| Publisher | Springer New York |
| Pages | 339-343 |
| Number of pages | 5 |
| ISBN (Electronic) | 9781461450610 |
| ISBN (Print) | 9781461450603 |
| DOIs | |
| State | Published - Jan 1 2013 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
}
Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Methotrexate
AU - Rosh, Joel
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Pharmacologic therapy for pediatric inflammatory bowel disease (IBD) can consist of topical therapies as well as those therapies that exert a direct effect on the host immune system. Traditionally, thiopurines have been the first line immunomodulatory agents used to treat pediatric IBD. Increasing awareness of rare but potentially life-threatening malignancies that have been associated with thiopurine use as well as cases of intolerance or lack of response to thiopurine agents has served to promote increasing utilization of another immunomodulator, methotrexate. Given once a week, either parenterally or orally, methotrexate has demonstrated efficacy in pediatric Crohn' disease with less proven efficacy in pediatric ulcerative colitis.
AB - Pharmacologic therapy for pediatric inflammatory bowel disease (IBD) can consist of topical therapies as well as those therapies that exert a direct effect on the host immune system. Traditionally, thiopurines have been the first line immunomodulatory agents used to treat pediatric IBD. Increasing awareness of rare but potentially life-threatening malignancies that have been associated with thiopurine use as well as cases of intolerance or lack of response to thiopurine agents has served to promote increasing utilization of another immunomodulator, methotrexate. Given once a week, either parenterally or orally, methotrexate has demonstrated efficacy in pediatric Crohn' disease with less proven efficacy in pediatric ulcerative colitis.
UR - http://www.scopus.com/inward/record.url?scp=84956667246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956667246&partnerID=8YFLogxK
U2 - 10.1007/978-1-4614-5061-0_32
DO - 10.1007/978-1-4614-5061-0_32
M3 - Chapter
AN - SCOPUS:84956667246
SN - 9781461450603
SP - 339
EP - 343
BT - Pediatric Inflammatory Bowel Disease, Second Edition
PB - Springer New York
ER -